TNFRSF1B and cancer: Contrary to the previous notion of anti-TNFR2 antibody-mediated CD8+ T cell co-stimulation, upcoming studies suggest that the anti-TNFR2 antibody activity is due to the blocking of TNFR2 to prevent TNF-α binding on both cancer cells and immune suppressive cells.